Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Louise Emmett, MD, PhD, MBChB, FRACP
Advertisement
Articles by Louise Emmett, MD, PhD, MBChB, FRACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5